AstraZeneca traded at 1,237.50 this Friday September 23rd, decreasing 7.00 or 0.56 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca lost 13.04 percent. Over the last 12 months, its price rose by 18.15 percent. Looking ahead, we forecast AstraZeneca to be priced at 1,203.10 by the end of this quarter and at 1,105.52 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1,237.50
Daily Change
-0.56%
Yearly
18.15%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Ovoca Bio PLC 8.80 -0.05 -0.57% -26.67%

Indexes Price Day Year
Stockholm 1818 -19.95 -1.09% -21.41%

AstraZeneca
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.